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Abstract: The tightly regulated process of precursor messenger RNA (pre-mRNA) alternative splicing
(AS) is a key mechanism in the regulation of gene expression. Defects in this regulatory process affect
cellular functions and are the cause of many human diseases. Recent advances in our understanding of
splicing regulation have led to the development of new tools for manipulating splicing for therapeutic
purposes. Several tools, including antisense oligonucleotides and trans-splicing, have been developed
to target and alter splicing to correct misregulated gene expression or to modulate transcript isoform
levels. At present, deregulated AS is recognized as an important area for therapeutic intervention.
Here, we summarize the major hallmarks of the splicing process, the clinical implications that arise
from alterations in this process, and the current tools that can be used to deliver, target, and correct
deficiencies of this key pre-mRNA processing event.
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1. Introduction
The Human Genome Project has revealed that there are approximately 20,000–25,000 protein-coding
genes [1]. The Human Proteome Map project [2] has so far identified more than 30,000 proteins from
approximately 293,000 peptides coded by approximately 17,000 human genes, and it is estimated that
the diversity of these protein-coding genes in humans is greatly increased by the presence of numerous
protein variants (isoforms). Several mechanisms are responsible for the formation of protein isoforms,
such as genetic variations, somatic recombination, post-translational and proteolytic modifications,
and alternative splicing (AS).
Genes are composed of introns and exons, but only exons contain the information necessary to
make proteins. AS of the pre-messenger RNA (mRNA) is a process by which the introns are removed
and the exons are appropriately aligned and ligated to form the mRNA. Human genes are composed
of an average of 7–8 introns and 8–9 exons. Considering that 3000 genes are actively transcribed at any
given moment and that every gene is capable of producing at least three transcripts, this results in
more than 60,000 introns that need to be simultaneously spliced [3]. Therefore, this process needs to be
efficiently spatiotemporally coordinated to yield a mature mRNA that is exported from the nucleus to
the cytoplasm to be translated into protein.
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In humans, >90% of genes undergo AS [4,5], underscoring the fundamental importance of this
regulatory process in expanding protein diversity through evolution. As such, the misregulation of AS
by mutations that affect the splicing signals or the splicing machinery itself is the cause of multiple
human diseases [6–8]. In this review, we aim to revisit current concepts and experimental observations
in therapeutic strategies to treat diseases arising from splicing defects, including advances in the
emerging field of nanotechnology.
2. Pre-mRNA Splicing
The splicing reaction is catalyzed by the spliceosome, a macromolecular complex formed by
five small nuclear ribonucleoproteins (snRNPs), termed U1, U2, U4, U5, and U6, and approximately
200 proteins [9]. The assembly of the spliceosome on pre-mRNA includes the binding of U1 snRNP,
U2 snRNP, the pre-formed U4/U6-U5 triple snRNP, and the Prp19 complex [10]. This assembly occurs
through the recognition of several sequence elements on the pre-mRNA that define the exon/intron
boundaries, which include the 5′ and 3′ splice sites (SS), the associated 3′ sequences for intron excision,
the polypyrimidine (Py) tract, and the branch point sequence (BPS). The assembly of the spliceosome
during the process of AS is depicted in Figure 1. In mammals, the first catalytic step of the splicing
reaction begins when the U1 snRNP binds the 5′ SS of the intron (defined by the consensus sequence
AGGURAGU), and the splicing factors SF1 and U2AF cooperatively recognize the BPS, Py, and
3′ SS to assembled complex E or the commitment complex [11,12]. Subsequently, U2 snRNP and
additional proteins are recruited to the pre-mRNA BPS to form the pre-spliceosome or complex
A [13]. The binding of the U4/U6-U5 tri-snRNP forms the pre-catalytic spliceosome or complex B [14].
After RNA-RNA and RNA-protein rearrangements at the heart of the spliceosome, U1 and U4 are
released [15] to form the activated complex B or complex B* This complex is responsible for executing
the first catalytic step, through which the phosphodiester bond at the 5′ SS of the intron is modified
by the 2′-hydroxyl of an adenosine of the BPS to form a free 5′ exon and a branched intron, which is
subsequently degraded. During this process, additional rearrangements occur to generate the catalytic
spliceosome or complex C, which is ultimately responsible for catalyzing the intron excision and
exon–exon ligation reactions. After the second catalytic step, the U2, U5, and U6 snRNPs are released
from the post-spliceosomal complex and recycled for additional rounds of splicing [16,17].
We know that additional sequence elements, known as exonic and intronic splicing
silencers or enhancers (ESS, ISS, ESE, and ISE, respectively), participate in the regulation of AS.
Specific RNA-binding proteins, including heterogeneous nuclear ribonucleoproteins (hnRNPs) and
serine/arginine-rich (SR) proteins, recognize these sequences to positively or negatively regulate AS
(Figure 2). These regulators, together with an ever-increasing number of additional auxiliary factors,
provide the basis for the specificity of this pre-mRNA processing event [18–20].
There are several different types of AS events, which can be classified into four main subgroups.
The first type is exon skipping, which is the major AS event in higher eukaryotes. In this type of
event, a cassette exon is removed from the pre-mRNA (Figure 3, panel a). The second and third types
are alternative 3′ and 5′ SS selection (Figure 3, panel b and c). These types of AS events occur when
the spliceosome recognizes two or more splice sites at one end of an exon. The fourth type is intron
retention (Figure 3, panel d), in which an intron remains in the mature mRNA transcript. This AS event
is much more common in plants, fungi and protozoa than in vertebrates. Other events that affect the
transcript isoform outcome include mutually exclusive exons (Figure 3, panel e), alternative promoter
usage (Figure 3, panel f), and alternative polyadenylation (Figure 3, panel g).
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Figure 1. Schematic representation of the spliceosome assembly and pre-mRNA splicing. In the
first step of the splicing process, the 5′ splice site (GU, 5′ SS) is bound by the U1 snRNP, and the
splicing factors SF1/BBP and U2AF cooperatively recognize the branch point sequence (BPS), the
polypyrimidine (Py) tract, and the 3′ splice site (AG, 3′ SS) to assemble complex E [11,12]. The binding
of the U2 snRNP to the BPS results in the pre-spliceosomal complex A [13]. Subsequent steps lead to
the binding of the U4/U5–U6 tri-snRNP and the formation of complex B [14]. Complex C is assembled
after rearrangements that detach the U1 and U4 snRNPs [15] to generate complex B*. Complex C is
responsible for the two trans-esterification reactions at the SS. Additional rearrangements result in the
excision of the intron, which is removed as a lariat RNA, and ligation of the exons. The U2, U5, and U6
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retention (Figure 3, panel d), in which an intron remains in the mature mRNA transcript. This AS 
event  is much more common  in plants,  fungi and protozoa  than  in vertebrates. Other events  that 
affect the transcript isoform outcome include mutually exclusive exons (Figure 3, panel e), alternative 
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Figure 2. AS regulation by cis elements and trans-acting factors. The core cis sequence elements
that define the exon/intron boundaries (5′ and 3′ splice sites (SS), GU-AG, polypyrimidine (Py)
tract, and branch point sequence (BPS)) are poorly conserved. Additional enhancer and silencer
elements in exons and in introns (ESE: exonic splicing enhancers; ESI: exonic splicing silencers; ISE:
intronic splicing enhancers; ISI: intronic splicing silencers) contribute to the specificity of AS regulation.
Trans-acting splicing factors, such as SR family proteins and heterogeneous nuclear ribonucleoprotein
particles (hnRNPs), bind to enhancers and silencers and interact with spliceosomal components [18–20].
In general, SR proteins bound to enhancers facilitate exon definition, and hnRNPs inhibit this process.
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Figure 3. Schematic representation of different types of alternative transcriptional or splicing events,
with exons (boxes) and introns (lines). Constitutive exons are shown in green and alternatively spliced
exons in purple. Dashed lines indicate the AS event. Exon skipping (a); alternative 3′ (b) and 5′ SS
selection (c); intron retention (d); mutually exclusive exons (e); alternative promoter usage (f); and
alternative polyadenylation (g) events are shown. Like alternative splicing (AS), usage of alternative
pro oter and polyadenylation sites allo a single gene to encode ultiple R A transcripts.
3. Connections between Splicing and Human Disease
As stated above, several diseases are caused by mistakes in the splicing process. These diseases
can be classified in two types depending on their origin: mutations in cis elements (i.e., affecting the
splicing signals) and mutations in trans elements (i.e., affecting the splicing machinery itself).
Mutations in the core splicing consensus sequences are known to lead to diseases. These mutations
can produce changes in the 5′ and 3′ SS and surrounding sequences or in the BPS or generate new SS
that may lead to disease when they are used. Alterations in the auxiliary cis elements described above
(the exonic and intronic splicing silencers or enhancers) may also lead to aberrant AS and cause disease.
As described above, the splicing reaction is a highly orchestrated process that requires the
fine-tuned coordination of a great number of proteins. Mutations in core spliceosome components or
auxiliary factors may disrupt, this mechanism in the cellular regulatory network and lead to diseases.
Because several reviews covering dysfunctions related to AS have been published elsewhere [7,8,21,22],
we do not aim to discuss specific examples here.
4. Therapeutic Approaches
Gene therapy has emerged as a promising pharmacotherapy option for patients with diseases of
genetic origin. During the last several decades, a diverse array of approaches to genetically modifying
a cell or organism has been investigated. Next, we discuss some strategies to treat diseases that have
been used to modify and fix errors in the splicing process and provide a summary of some diseases
affecting this process that might be a target for gene therapy (Table 1).
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Table 1. Summary of splicing-related diseases that might be target for gene therapy.
Disease Regulatory Element Mutated Mechanism Splicing Effect References
Familial dysautonomia (FD) Cis T > C mutation at position 6 of intron 20 ofthe IKBKAP gene
Exon skipping; introduction of a premature
termination codon (PTC) [23]
Spinal muscular atrophy (SMA) Cis C > T mutation at position 6 of exon 7 of theSMN2 gene Alteration of a putative ESE [24]
Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency Cis c362C > T mutation in exon 5 of theMCAD gene Exon skipping [25]
Hutchinson-Gilford progeria syndrome (HGPS) Cis c1824C > T mutation in exon 11 ofLMNA gene Activation of a cryptic splice site [26]
Myotonic dystrophy
Type 1 (DM1) Cis Expanded CTG tract in the 3
′ UTR region of
the DMPK gene Misregulation of trans-acting factors [27]
Type 2 (DM2) Cis Expanded CCCTG tract in intron 1 of theZNF9 gene Misregulation of trans-acting factors [27]
Autosomal dominant retinitis pigmentosa (RP) Trans Mutations in genes of the core spliceosome(PRPF31, PRPF8, PRPF3, RP9) Disruption of basal spliceosome function [28]
Duchenne muscular dystrophy (DMD) Cis T > A mutation in exon 31 of theDistrophin gene Creation of a PTC and introduction of ESS [29]
Microcephalic steodysplastic primordial dwarfism type 1 (MOPD1) or
Taybi-Linder syndrome (TALS) Trans
Mutations in the gene encoding the
U4atac snRNA
Reduced splicing efficiency and increased
intron retention [30]
Frontotemporal dementia with parkinsonism-17 (FTDP-17) Cis Mutations within and downstream exon 10of the MAPT gene Disruption of Tau protein balance [31]
Fukuyama congenital muscular dystrophy (FCMD) Cis SVA insertion in the 3
′ UTR of the
FKTN gene Inclusion of a new exon [32]
Amyotrophic lateral sclerosis (ALS) Trans Mutations in TDP-43 Altered gene splicing [33]
Hypercholesterolemia Cis rs688T > C mutation in exon 12 of theLDLR gene Alteration of ESE and exon skipping [34]
Cystic fibrosis (CF) Cis Longer (UG)n tract at the exon 9 3
′ SS of the
CFTR gene Exon skipping [35]
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4.1. Antisense Oligonucleotides (ASOs)
This strategy is based on short oligonucleotides that are guided to the pre-mRNA to modify
the splicing process. ASOs can be designed to target the SS or auxiliary sequences (see above) to
modify the outcome of the splicing reaction, thereby leading to mRNA repair and the restoration
of protein function [36]. These splicing-related ASOs act through a different mechanism of action
than conventional antisense oligonucleotides or siRNA (see below), which inhibit gene expression
by degrading the target mRNA. These sequences sterically block relevant motifs in the pre-mRNA
without promoting degradation while shifting the splicing outcome (Figure 4, panel a). For this reason,
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BCL2L1  pre‐mRNA  to  promote  apoptosis  in  cancer  cells  in  culture  [39].  These  bifunctional 
oligonucleotides  to  alter  splicing  decisions  can  be  used  against  a  wide  range  of  targets  [40]. 
Frequently, ASOs are chemically modified to improve binding affinity and avoid degradation. 
Figure 4. Three different strategies to target splicing for gene modification. (a) The diagram depicts
an antisense oligonucleotide (ASO)-based strategy to target an alternatively spliced exon (in orange).
In the absence of the ASO, the spliceosome is assembled and the exon is included in the mRNA; in the
presence of the ASO, the spliceosome is sterically blocked and the exon is skipped and not included in
the mRNA. (b) SMaRT strategy for trans-splicing by 5′ exon replacement. Schematic representation of
the gene-specific pre-trans-splicing molecule (PTM). The coding sequence of the PTM consists of an exon
(in green), and the trans-splicing domain of the PTM comprises a binding-domain (BD) complementary
to the 3′ end of the gene intron as well as highly conserved BPS and Py sequences. (c) Illustration
depicting the mechanism by which siRNA can inhibit the expression of specific exon-containing
target gene products by hybridizing to the mRNA and triggering RISC-mediated degradation or
translational inhibition.
splice switching strategy is to fuse the RNA s qu nce that is co plementary to an
RNA binding motif (the ASO) with an untethered RNA segment that erv s as a sequence-specific
binding platform for the recruitment of a splicing silencer or activator to the targeted RNA (TOSS
and TOES, respectively, for targeted l gonucleotide silencer of splicing and targeted oligonucleotide
enhan er of splicing) [37]. This approach was used to red rect the splicing to favor the i clusion of
ndogenous exon 7 SMN2 transcript to incr ase the level of functional SMN protein [38] and to alter
AS of the BCL2L1 pre-mRNA t prom te apoptosis in cancer cells in c lture [39]. These
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oligonucleotides to alter splicing decisions can be used against a wide range of targets [40]. Frequently,
ASOs are chemically modified to improve binding affinity and avoid degradation.
Among the best characterized medical examples of the use of ASOs is in the treatment of
Duchenne muscular dystrophy (DMD). DMD is a genetic disorder characterized by progressive
muscle degeneration and weakness caused by the alteration of dystrophin, which anchors the
extracellular matrix to the cytoskeleton of muscle fibers. The DMD gene is the largest known
human gene with 79 exons. Deletion mutations have been identified in approximately two-thirds
of DMD cases and the clinical variation in phenotype correlates with the maintenance or disruption
of the translational open reading frame of the mRNA [41]. An antisense-mediated approach to
restore the reading frame by targeting exons flanking frame-shift deletions functionality was one
of the methods devised early on [42,43]. These early promising results were confirmed by several
other studies using antisense-mediated restoration of the reading frame as a therapy for Duchenne
patients [44–46]. Very recently, a phosphorodiamidate morpholino oligomer (PMO) designed to induce
exon 51 skipping (Eteplirsen/Exondys 51) has received accelerated approval from the U.S. Food and
Drug Administration (FDA) for the treatment of DMD [47,48].
Spinal muscular atrophy (SMA) is a disease caused by mutations and deletions in the survival
motor neuron 1 (SMN1) gene that can be partially compensated for by increasing the inclusion of
exon 7 in the second copy gene SMN2. In a series of seminal articles, Krainer’s group showed that
appropriate 2′-O-(2-methoxyethyl) (MOE) phosphorothioate-modified ASOs can efficiently correct
SMN2 exon 7 splicing. Importantly, this splicing correction was achieved in cultured human cells
(including patient fibroblasts) and in induced mouse models of SMA [49–52]. These results led to the
development of nusinersen (Spinraza), an ASO that after extensive preclinical and clinical testing [53]
has been approved on December 23 by the FDA under Priority Review for the treatment of SMA
in pediatric and adult patients. These are perfect examples of how basic research focused on the
mechanisms of disease is key to important clinical developments.
Antisense derivatives of U7 snRNP can also redirect splicing towards the synthesis of the exon
7-containing SMN2 protein in cultured cells and SMA mouse models [54,55], which support the
usefulness of ASOs as promising therapeutic drugs [56].
The ASO strategy has also been successfully used for targeting the pre-mRNA to restore
prematurely stopped open reading frames, such as in the inherited disease dystrophic epidermolysis
bullosa (DEB) [57], induce isotype switching of the Tau mRNA in the frontotemporal dementia and
parkinsonism linked to chromosome 17 (FTDP-17) [58], generate a truncated APOB100 protein with
therapeutic utility to prevent the development of atherosclerosis [59], or induce exon inclusion of the
exon necessary for the treatment of cystic fibrosis [60].
4.2. Spliceosome-Mediated RNA Trans-Splicing (SMaRT)
SMaRT is a system used to reprogram mRNA that introduces into cells the part of the mutant
transcript that has to be corrected instead of a full-length cDNA sequence. In brief, the SMaRT
technology needs three components. Two of them are provided by the cell: the spliceosome machinery
and the target mRNA. The third component of the system, which has to be introduced into the cell,
is the pre-trans-splicing molecule (PTM) (also termed RNA trans-splicing molecule or RTM). The
final goal is to recombine the endogenous mutated target pre-mRNA with the exogenous PTM and
achieve the substitution of the mutated region for the wild-type sequence [61]. Designing a correct
PTM is crucial for the reprogramming of mRNA. The PTM must carry the wild-type coding region
of the gene that is to be replaced, 5′ and 3′ SS, intronic BPS and Py sequences, and a complementary
sequence or binding domain for precise and specific hybridization to the mutated pre-mRNA (Figure 4,
panel b) [62,63].
There are three types of SMaRT approaches: 5′-trans-splicing, 3′-trans-splicing, and internal
exon replacement (IER), which target the 5′-, 3′-, or internal portion of a mutated target pre-mRNA,
respectively. In the last few years, there have been several examples of the use of the SMaRT strategy as
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a tool for treating genetic diseases. Early pioneering work using HeLa nuclear extracts, cultured human
lung cancer cells, and tumor-bearing athymic (nude) mice suggested that SMaRT could represent
a general approach for reprogramming the sequence of targeted transcripts [64]. Subsequently, the
same group demonstrated the feasibility of the system by repairing mutations in the cystic fibrosis
trans-membrane conductance regulator (CFTR) gene using a 5′-exon replacement approach [65], which
was followed by a study showing that SMaRT can efficiently promote the production of a functional
protein in vitro [66]. Another example of using SMaRT to reprogram mRNA is the correction of the Tau
isoform imbalance that is characteristic of FTDP-17 and tauopathies [67–69]. Recently, the trans-splicing
system has been optimized through the combination of the trans-splicing RNA and antisense RNA
interfering with competitive splicing elements on the pre-mRNA [70,71]. A comprehensive review
detailing the use of SMaRT in gene therapy for genetic diseases has been recently published [63].
4.3. Small Interfering RNAs (siRNAs)
One of the most important advances in the field of molecular biology is the use of siRNAs to
silence the expression of genes. The administration of RNA of 21–23 nucleotides (nt) in length can
prevent the translation of an endogenous mRNA through its base pairing with the target to induce
degradation or translation inhibition depending on the degree of complementarity (Figure 4, panel c).
Targeting aberrant splicing isoforms is one of the many potential therapeutic uses of siRNAs. Exonic,
intronic, and exonic/intronic junction sequences have been used to design siRNAs to specifically
degrade aberrant or alternatively spliced mRNAs. This targeting approach was used, among others, in
the fibronectin gene, Ullrich congenital muscular dystrophy (UCMD), and growth hormone deficiency
(GHD) type II diseases [72–74].
Some of the mentioned examples about therapeutic approaches to modulate splicing are
summarized in Table 2.
Table 2. Examples of splicing-based therapeutic approaches (see text for details).
Disease Therapeutic Approach Target Gene Regulated Exon
DMD ASO DMD 51
SMA ASO SMN2 7








Ullrich congenital muscular dystrophy
(UCMD) siRNA COL6A3 16
Growth hormone deficiency (GHD)
type II siRNA GH1 3
5. Delivery Methods
One of the main challenges in gene therapy is the delivery of foreign genes to human
patients. Today, viral and non-viral methods are used for delivering genes and biomolecules in vivo.
Both approaches have advantages and disadvantages, which we briefly analyze.
5.1. Viral Methods
The use of viruses such as retrovirus, adenovirus or adeno-associated virus (AAV), among
others, is one of the most successful gene therapy systems available today. The administration of
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viral vectors to human patients is done by direct injection into target tissues or by the injection of
viral-modified cells [75]. The most important advantage of viruses as vectors for gene delivery is
their high transfection efficiency. However, the system has some disadvantages, such as their marked
immunogenicity, the phenotoxicity of the transgene, and potential vertical and horizontal transmission
by replication-competent viruses. More recently, viruses have been appropriately modified to minimize
the associated immunogenicity while introducing the therapeutic gene unit in its genome, e.g., by
replacing viral pathogenic elements [76]. When using retroviral and lentiviral vectors, integration into
the host genome poses a risk of vector-mediated alterations in cells that are relevant for gene therapy
applications. In support of this statement, a whole transcriptome analysis of aberrant splicing events
occurring upon lentiviral vector transduction has been reported [77]. Multi-drug resistance elicited
by viral vectors, such as Adenovirus, may affect the efficacy of chemotherapy, thus limiting the use
of these vectors [78]. Problems with scaling up production processes and high economic costs are
also barriers that need to be improved when considering viral vectors to treat diseases. Several recent
reviews covering specific aspects of the use of viral vectors for gene therapy have been published
elsewhere [75,79,80]. Aspects such as the insert size, time-course of transgene expression, route
administration, and gene targeting are of primary importance when choosing the right viral vector.
Viral vectors have been used in certain cases of human diseases by changing the splicing pattern
(even if the origin of the disease is not strictly related to the splicing process) such in SMA [81–83],
DMD [84–88], cystic fibrosis [89,90], retinitis pigmentosa [91,92], aromatic L-amino acid decarboxylase
(AADC) deficiency [93], UDP N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE)
myopathy [94], Fanconi anemia C (FANCC) [95], and retinal disease [96].
5.2. Non-Viral Methods
In recent decades, nanoparticle-mediated delivery of biomolecules has received much attention
for its potential to modulate the regulation of gene expression for the treatment of diseases, thus
representing a promising new avenue for gene therapy [97–100]. The advantages of non-viral gene
delivery systems compared to viral systems are clear in terms of the immunogenic responses. Whereas
low immunogenicity is a positive trait, one obstacle of these non-viral delivery systems is the low
transfection efficiency [101]. There are few reports where nanoparticles have achieved high gene
transfection efficiency with values approaching those obtained using viral vectors [102].
In recent years, the use of nanodelivery systems of different materials and the physiochemical
properties necessary for the cellular uptake of biomolecules has become particularly important.
There are a variety of different nanoparticle types, depending on manufacturing processes and
components (Figure 5) [103]. The nanoparticle formula can be designed to produce carriers for
oral [104], skin [105], liver [106], pulmonary [107], brain [108], or cancer targeting [109]. Nanoparticles
can be used to deliver a combination of biomolecules to enhance the therapeutic effect against disease.
For example, Liu et al. developed multifunctional nanoparticles carrying an inhibitory peptide and an
shRNA for the treatment of Alzheimer’s disease, thus acting in relevant pathways in the pathogenesis
of the disease [110]. The successful co-delivery of biomolecules overcoming the blood–brain barrier
makes this type of nanostructured system useful for improving therapeutic delivery to the brain [108].
Nanoparticles can be used for delivering RNA in order to achieve controlled and selective
therapeutic effects acting on the splicing process. To deliver these nanoparticles into cells where they
display full bioactivity at nontoxic concentrations, recent studies have focused on understanding the
effects of nanoparticle physicochemical properties [111]. Several formulations have been shown to
effectively target diseased tissues to redirect the AS of pre-mRNA. Administration of lipid nanoparticles
with BCL2L1 ASO resulted in modification of BCL2L1 pre-mRNA splicing to induce apoptosis and
subsequent cell death in lung metastases. Redirection of BCL2L1 pre-mRNA splicing was associated
with reduced tumor load [112]. Chitosan-based nanoparticles have been successfully used to deliver
intronic ASOs into embryonic and lymphoblastoid cells to modulate ataxia-telangiectasia mutated
(ATM) gene expression [113], which is an interesting and promising target for anticancer therapy.
Genes 2017, 8, 87 10 of 17
In mice, cationic polymethylmethacrylate (PMMA) nanoparticles loaded with 2′OMePS delivered by
intraperitoneal injections could restore dystrophin expression in skeletal and cardiac muscle [114,115],
thereby showing the potential of this method for ASO delivery in DMD. Functional delivery by
polyethylenimine nanoparticles of ASO conjugated to a bivalent arginine–glycine-aspartic acid
(RGD) peptide, which specifically binds to integrin αvβ3, demonstrated dramatic increase in the
pharmacological response of splicing correction through integrin-mediated endocytosis and rapid
endosomal release [116]. Polyamidoamine (PAMAM) dendrimers are cationic polymers that have also
been used to deliver 2′-O-methyl antisense oligonucleotides to correct splicing at an aberrant intron
inserted into a luciferase reporter gene [117,118]. In conclusion, these results show great promise of
using nanomaterials as nucleic acid vehicles to target and interfere with the splicing process.
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Figure 5. Schematic representation of different types of nanoparticles used to deliver biomolecules.
(a) Solid lipid nanoparticles (SLNs); (b) Polymeric nanoparticles; (c) Inorganic core-shell nanoparticles
(Au: gold, Fe3O4: iron oxide); (d) Lipid bilayer-based liposomes.
Despite these remarkable in vitro and in vivo results using nanoparticle-mediated delivery
to target splicing events, the translational progress for medical applications has been limited.
Poor delivery efficiency and the inability to control the nanoparticle transport inside the body are
major limitations that need to be overcome for the clinical translation of nanomedicine [119].
6. Conclusions
AS is an essential component of gene expression regulation that contributes to the diversity of cell
and tissue-specific protein expression profiles. In recent decades, we have increased our knowledge
of the mechanisms and compositional dynamics of how exons are alternatively spliced to generate a
plethora of transcript isoforms. These studies give rise to important new basic questions regarding
AS regulation to better understand this interesting and critical aspect of RNA biogenesis. Because of
the connections between AS and disease, further studies are necessary to provide relevant insights
into the molecular mechanisms involved in human disease. A step of considerable importance and
an exciting concept is the possibility of targeting the splicing process for therapy. As outlined in this
review, several approaches have been devised to modify the outcome of the splicing reaction to treat
genetic diseases caused by splicing errors. Extensive studies have been performed, and a series of
benchmark results have shown the proof of concept and the feasibility of this approach to make a real
impact on gene therapy. However, these laboratory studies will unlikely translate to the clinic without
a specific, efficient, and safe delivery system easily translatable to human patients. In recent years,
the use of nanoparticles as transport systems for the delivery of drugs and biomolecules has received
much attention, especially to detect and destroy cancer cells. Although nanotechnology has been
successfully used for the delivery of molecules to redirect the splicing of pre-mRNA, it is important to
address the barriers associated with delivery efficiency and transport inside the body to accelerate the
clinical translation of this innovative splicing-targeting approach for therapy.
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